143 related articles for article (PubMed ID: 12642867)
1. Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells.
Yamashita H; Iwase H; Toyama T; Fujii Y
Oncogene; 2003 Mar; 22(11):1638-52. PubMed ID: 12642867
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.
Shipley JM; Waxman DJ
Mol Pharmacol; 2003 Aug; 64(2):355-64. PubMed ID: 12869640
[TBL] [Abstract][Full Text] [Related]
3. Differential function of STAT5 isoforms in head and neck cancer growth control.
Leong PL; Xi S; Drenning SD; Dyer KF; Wentzel AL; Lerner EC; Smithgall TE; Grandis JR
Oncogene; 2002 Apr; 21(18):2846-53. PubMed ID: 11973644
[TBL] [Abstract][Full Text] [Related]
4. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells.
Baśkiewicz-Masiuk M; Machaliński B
Eur J Haematol; 2004 Jun; 72(6):420-9. PubMed ID: 15128421
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 induces apoptosis of 697 pre-B cells expressing dominant-negative forms of STAT5: evidence for caspase-dependent and -independent mechanisms.
Lanvin O; Gouilleux F; Mullié C; Mazière C; Fuentes V; Bissac E; Dantin F; Mazière JC; Régnier A; Lassoued K; Gouilleux-Gruart V
Oncogene; 2004 Apr; 23(17):3040-7. PubMed ID: 15048088
[TBL] [Abstract][Full Text] [Related]
6. ERalpha and STAT5a cross-talk: interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation and DNA-binding.
Wang Y; Cheng CH
FEBS Lett; 2004 Aug; 572(1-3):238-44. PubMed ID: 15304355
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.
Shipley JM; Waxman DJ
Toxicol Appl Pharmacol; 2004 Sep; 199(3):275-84. PubMed ID: 15364543
[TBL] [Abstract][Full Text] [Related]
8. The role of Stat5 in estrogen receptor-positive breast cancer.
Yamashita H; Iwase H
Breast Cancer; 2002; 9(4):312-8. PubMed ID: 12459712
[TBL] [Abstract][Full Text] [Related]
9. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.
Kieslinger M; Woldman I; Moriggl R; Hofmann J; Marine JC; Ihle JN; Beug H; Decker T
Genes Dev; 2000 Jan; 14(2):232-44. PubMed ID: 10652277
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
Jacobberger JW; Sramkoski RM; Frisa PS; Ye PP; Gottlieb MA; Hedley DW; Shankey TV; Smith BL; Paniagua M; Goolsby CL
Cytometry A; 2003 Aug; 54(2):75-88. PubMed ID: 12879454
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice.
Yamashita H; Nishio M; Fujii Y; Iwase H
Cancer Sci; 2004 Aug; 95(8):662-5. PubMed ID: 15298729
[TBL] [Abstract][Full Text] [Related]
12. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity.
Park SH; Yamashita H; Rui H; Waxman DJ
Mol Endocrinol; 2001 Dec; 15(12):2157-71. PubMed ID: 11731617
[TBL] [Abstract][Full Text] [Related]
13. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
14. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
Yamashita H; Nishio M; Ando Y; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437
[TBL] [Abstract][Full Text] [Related]
15. The role of STAT5 proteins in the regulation of normal hematopoiesis in a cord blood model.
Baśkiewicz-Masiuk M; Masiuk M; Czajka R; Machaliński B
Cell Mol Biol Lett; 2003; 8(2):317-31. PubMed ID: 12813566
[TBL] [Abstract][Full Text] [Related]
16. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H
J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792
[TBL] [Abstract][Full Text] [Related]
17. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis.
Yamada K; Ariyoshi K; Onishi M; Miyajima A; Hayakawa F; Towatari M; Saito H; Oka Y; Asano S; Nosaka T; Kitamura T
Int J Hematol; 2000 Jan; 71(1):46-54. PubMed ID: 10729993
[TBL] [Abstract][Full Text] [Related]
18. Possible role of Stat5a in rat mammary gland carcinogenesis.
Shan L; Yu M; Clark BD; Snyderwine EG
Breast Cancer Res Treat; 2004 Dec; 88(3):263-72. PubMed ID: 15609129
[TBL] [Abstract][Full Text] [Related]
19. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system.
Kazansky AV; Spencer DM; Greenberg NM
Cancer Res; 2003 Dec; 63(24):8757-62. PubMed ID: 14695191
[TBL] [Abstract][Full Text] [Related]
20. Coactivators in gene regulation by STAT5.
Litterst CM; Kliem S; Lodrini M; Pfitzner E
Vitam Horm; 2005; 70():359-86. PubMed ID: 15727811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
